Creating Humabody™
fully-human VH
therapeutics

Crescendo Biologics is a drug discovery and development company in oncology based on its proprietary Humabody™ VH technology. 

The Company is building a pipeline of new therapeutics through in-house development and strategic partnerships. The discovery programmes are focused on the development of innovative medicines for the treatment of cancer, including Humabody™ Drug Conjugates (HDCs) and checkpoint modulators such as anti-PD-1 Humabodies™.

News & Events
Feb 2, 2016
Crescendo Biologics Appoints Dr Barbara Fleck as Head of...
Nov 17, 2015
Crescendo Appoints New Chairman
© 2014 Crescendo Biologics